San Miguel J F, García-Sanz R
Hematology Service, University Hospital of Salamanca, Spain.
Med Oncol. 1998 Aug;15 Suppl 1:S29-34.
Recombinant human erythropoietin has been recently introduced as an important alternative for treatment of anaemia in multiple myeloma and non-Hodgkin's lymphoma. In the present paper we review the basis for its use in the anaemia of both entities, and the most relevant clinical trials showing the effect of erythropoietin. In MM patients the response rate (assessed by an increase of at least 2g/dl in the Hb level) ranges between 60%-80% while in NHL patients it ranges from 50% to 61%. The most appropriate EPO dose is around 5000 units per day, which is equivalent to 150 u/kg, three times per week. In addition, this review provides tools to decide the best candidates for this treatment and a guideline to monitor its efficacy.
重组人促红细胞生成素最近已被引入，作为治疗多发性骨髓瘤和非霍奇金淋巴瘤贫血的重要替代方法。在本文中，我们回顾了其用于这两种疾病贫血治疗的依据，以及显示促红细胞生成素疗效的最相关临床试验。在多发性骨髓瘤患者中，缓解率（通过血红蛋白水平至少增加2g/dl评估）在60%-80%之间，而在非霍奇金淋巴瘤患者中，缓解率在50%至61%之间。最合适的促红细胞生成素剂量约为每天5000单位，相当于150u/kg，每周三次。此外，本综述提供了确定该治疗最佳候选者的工具以及监测其疗效的指南。
